More reads

• NYSE cuts fees to court biotech listings away from Nasdaq. (Wall Street Journal)
• Vertex and U.K. agency are still haggling over cystic fibrosis drugs. (STAT Plus)
• Biotech tide may turn as large deals are shunned, Citi says. (Bloomberg)
• Glaxo revamps sales rep compensation as part of an effort to compete in the cancer market. (STAT Plus)